Why InterMune, Inc. Shares Popped
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company InterMune, Inc. climbed 10% today after its preliminary Q4 results impressed Wall Street.
So what: InterMune shares have soared on strong global penetration of its franchise lung disease drug Esbriet, and the current-quarter outlook -- management expects Esbriet revenue growth of 212% in Q4 -- coupled with upbeat full-year guidance suggests that the trend is accelerating. So while a good portion of Esbriet's long-term prospects still depend on its approval in the U.S. (the drug initially rejected by the FDA in 2010), InterMune's surging global sales are prompting analysts to increase their valuation estimates.
Now what: InterMune now expects Esbriet revenue growth of 65% to 90% in 2014. "As we closed out 2013, we announced our progress and planned investments in our growing R&D pipeline that build on our commercial momentum with Esbriet, leverage our expertise in IPF and fibrosis and move us toward realizing our strategic vision of becoming a leader in specialty fibrotic diseases," said Chairman and CEO Dan Welch. Of course, with management still set to communicate top-line results from the U.S. ASCEND study in the second quarter of 2014, I wouldn't bet too much on that optimism just yet.
More compelling ways to grow
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen 6 picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
The article Why InterMune, Inc. Shares Popped originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.